Intrathecal Rituximab With Standard Intrathecal Prophylaxis to Prevent CNS Relapse for CD 20+ Non Hodgkin Lymphoma
| Status: | Recruiting |
|---|---|
| Conditions: | Lymphoma, Lymphoma |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 9/30/2018 |
| Start Date: | October 2018 |
| End Date: | October 2023 |
| Contact: | UC Cancer Institute Clinical Trials Office |
| Email: | cancer@uchealth.com |
| Phone: | 513-584-7698 |
A Pilot Study to Access the Feasibility and Safety of Intrathecal Rituximab Added to Standard Intrathecal Prophylaxis to Prevent CNS Relapse for CD 20 Positive Non Hodgkin Lymphoma
The purpose of this research study is to learn if giving rituximab, the study drug, right
into the spinal canal along with chemotherapy drugs like methotrexate is possible and safe.
into the spinal canal along with chemotherapy drugs like methotrexate is possible and safe.
Inclusion Criteria:
- CD20 positive diffuse large b-cell lymphoma undergoing treatment with systemic
rituximab in combination with CHOP, CHOEP, or EPOCH and deemed high risk of CNS
relapse and eligible for central nervous system prophylaxis with intrathecal therapy.
Exclusion Criteria:
- Primary central nervous system lymphoma or established secondary central nervous
system disease.
- History of spinal surgery and/or ineligible for intrathecal injections.
We found this trial at
1
site
Click here to add this to my saved trials
